(Q31918096)

English

Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

multicenter clinical trial

0 references

author name string

Winston DJ

1

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Lazarus HM

2

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Beveridge RA

3

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Hathorn JW

4

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Gucalp R

5

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Ramphal R

6

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Chow AW

7

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Ho WG

8

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Horn R

9

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Feld R

10

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Louie TJ

11

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Territo MC

12

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Blumer JL

13

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Tack KJ

14

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

language of work or name

0 references

publication date

30 January 2001

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

381-390

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

Randomized comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer).

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Tre

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

In vitro activity of PD 127,391, an enhanced-spectrum quinolone

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

Management of fever in patients with cancer and treatment-induced neutropenia

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

Intravenous ciprofloxacin for infections in cancer patients

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of C

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

New uses for new and old quinolones and the challenge of resistance

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

Bacteremia due to viridans streptococci in neutropenic patients: a review

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

Temafloxacin syndrome: review of 95 cases

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

Increase in insulin release from rat pancreatic islets by quinolone antibiotics

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1086%2F318500

21 January 2018

Identifiers

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

release_wzheidcxobh67eomeoomfrix3q

1 reference

https://api.fatcat.wiki/v0/release/wzheidcxobh67eomeoomfrix3q

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31918096&oldid=1838599472"